News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Guilford Pharmaceuticals Receives European Marketing Authorization for Expanded Use of GLIADEL(R) Wafer - GLIADEL(R) Approved to Treat Newly-Diagnosed Patients with Malignant Glioma


Posted on: 09/16/2004

Guilford Pharmaceuticals Receives European Marketing Authorization for Expanded Use of GLIADEL(R) Wafer - GLIADEL(R) Approved to Treat Newly-Diagnosed Patients with Malignant Glioma

BALTIMORE, Sept. 14 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) today announced that its proprietary treatment for brain cancer, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), has been granted extended marketing authorization in Europe to include use in newly- diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. Under the mutual recognition procedure, GLIADEL(R) has been approved for use in the following countries: France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain and the United Kingdom. GLIADEL(R) was previously authorized for use only in recurrent surgery for glioblastoma multiforme.


















Click HERE to return to brain tumor news headlines




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740